CN106518859B - Thiazole derivative and its preparation method and application - Google Patents
Thiazole derivative and its preparation method and application Download PDFInfo
- Publication number
- CN106518859B CN106518859B CN201610928140.4A CN201610928140A CN106518859B CN 106518859 B CN106518859 B CN 106518859B CN 201610928140 A CN201610928140 A CN 201610928140A CN 106518859 B CN106518859 B CN 106518859B
- Authority
- CN
- China
- Prior art keywords
- compound
- general formula
- pharmaceutical composition
- thiazole
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the new thiazole derivatives and its pharmaceutically acceptable salt with logical formula (I) structure, wherein each group definition is as used in the description.The invention further relates to the preparation method of the compound, containing they pharmaceutical composition and its as bioactive substance be used to prepare prevention and/or treat thrombotic disease drug purposes.
Description
Technical field
The present invention relates to anticoagulant fields, specifically the present invention relates to new thiazole derivative, preparation method and its
It is being used to prepare prevention and/or is treating the purposes of thrombotic disease drug or pharmaceutical composition.
Background technique
In the angiocarpy of people, blood occurs certain visible components precipitations, agglutination in solidification or blood and forms solid mass
Process, referred to as thrombosis, being formed by solid mass is thrombus.Blood clotting was a kind of protection machine of organism originally
System, however, triggering abnormal coagulation process, blood in the case where blood flow anomalies, blood vessel change in wall or coagulation factor exception
Liquid can form thrombus or embolism, so as to cause thromboembolisms such as myocardial infarction, apoplexy, deep vein thrombosis or pulmonary embolism
Property disease.Thrombotic disease is the disease that most serious is endangered in cardiovascular disease, is the first killer of human health.
The drug of existing antithrombotic embolism class diseases is divided into antiplatelet drug, anticoagulation medicine and fibrinolytic drug
Object.Wherein, anticoagulation medicine mainly has thrombin inhibitor, vitamin K antagon and Xa factor inhibitor.With heparin and low point
Sub- heparin is that the thrombin inhibitor of representative has the disadvantages of taking orally invalid, non-selective inhibition and High risk of bleeding.With magnificent method
Although the vitamin K antagon that Lin Wei is represented can take orally, therapeutic index is narrow, big with food drug interaction, individual
Dose difference is also bigger.
Studies have shown that Xa factor is the best target of development of new anticoagulant, have razaxaban, Eliquis at present
It is listed with edoxaban.The direct inhibition of Xa factor can generate efficient blood coagulation resisting function, and without thrombin inhibitor
Side effect.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of completely new thiazole derivative, which has anticoagulant work
With, can be used in prevent and/or treat thrombotic disease.
In order to solve the above technical problems, there is the structure as shown in formula (I) the present invention provides a kind of compound:
Or its pharmaceutically acceptable salt, in which:
R1Selected from fluorine, chlorine, bromine；
R2Selected from hydrogen, fluorine, chlorine, methyl.
Preferably, the compound of the present invention is selected from following compounds:
I-1:N- (4- chlorphenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4- first
Amide；
I-2:N- (4- bromophenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4- first
Amide；
I-3:N- (4- bromophenyl) -2- ((the fluoro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -
4- formamide；
I-4:N- (4- fluorophenyl) -2- ((2- methyl -4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiophene
Azoles -4- formamide；
I-5:N- (4- chlorphenyl) 2- ((the chloro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -
4- formamide；
Or its pharmaceutically acceptable salt.
The compound pharmaceutically acceptable salt of logical formula (I) of the present invention, both officinal salt, was logical formula (I) structure
Compound and various inorganic acids (including but not limited to, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid) or organic acid (including
But it is not limited to, such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, malic acid, citric acid, oxalic acid, fumaric acid, maleic acid, amino acid, first
Sulfonic acid, ethanesulfonic acid, benzene sulfonic acid etc.) generate salt.
The compound pharmaceutically acceptable salt of logical formula (I) of the present invention, both officinal salt, can also be logical formula (I)
The compound of structure and various alkaline matters (hydroxide, carbonate or the bicarbonate of such as alkali or alkaline earth metal, including
But be not limited to: sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate etc.) generate salt, such as corresponding sodium salt, sylvite or calcium salt
Deng.Nontoxic organic base such as methylamine, triethylamine or meglumine etc. can also be used and generate salt.
The compound of the present invention is synthesized by following steps:
Wherein: R1Selected from fluorine, chlorine, bromine；R2Selected from hydrogen, fluorine, chlorine, methyl；
The compound of general formula (VIII) reacts the compound for preparing general formula (VII) with chloracetyl chloride in a solvent；General formula (VII)
Compound prepares the compound of general formula (VI) with potassium rhodanide or sodium sulfocyanate reaction in a solvent；The compound of general formula (VI) with
The compound of general formula (V) reacts the compound for generating general formula (IV) in a solvent；The compound of general formula (IV) is logical through hydrolysis preparation
The compound of formula (III)；The compound of general formula (III) reacts the change for generating general formula (I) with the compound of general formula (II) in a solvent
Close object.
Wherein, the compound of general formula (II), (V) and (VIII) can be obtained by commercial sources, such as lark prestige, Ah method's Sha's public affairs
Department, can also be prepared by known method.
Wherein, solvent used in preparation method refers to inert organic solvent at reaction conditions, including but not limited to,
Ether, such as tetrahydrofuran, ether, glycol dimethyl ether；Halogenated hydrocarbons, such as 1,2- dichloroethanes, methylene chloride, chloroform, four
Chlorination carbon etc.；Alcohol, such as methanol, ethyl alcohol, isopropanol, the tert-butyl alcohol；Hydrocarbon, such as benzene,toluene,xylene, hexane, hexamethylene；Its
It, such as dimethyl sulfoxide, dimethylformamide, acetonitrile, pyridine, water, hexamethylphosphoric triamide.Solvent can also be above-mentioned molten
The mixture of agent.
Wherein, in preparation method, can also add in the reaction of synthesis general formula VII, general formula IV, general formula III and general formula I
Entering alkali, suitable alkali can be conventional inorganic base or organic base in reaction, including but not limited to, the hydroxide of alkali metal,
Such as potassium hydroxide or sodium hydroxide；The carbonate of alkali metal, such as potassium carbonate or sodium carbonate；Alkoxide, such as sodium methoxide, methanol
Potassium, sodium ethoxide, potassium ethoxide or potassium tert-butoxide etc.；Amine, such as methylamine, hydrazine hydrate, triethylamine, diisopropylethylamine, pyridine.Alkali
It is 1~5 mole, preferably 1~2 mole that dosage, which is based on 1 molar reactive substrate,.
Reaction can carry out at various pressures, such as decompression, normal pressure or pressurization, preferably carry out under normal pressure.
Reaction generally -78 DEG C to reflux temperature at a temperature of carry out, preferably 0 DEG C to reflux temperature of range carries out.
The compound or pharmaceutically acceptable salt thereof of logical formula (I) structure of the invention can play anticoagulation by inhibition Xa,
Therefore it can be used for preparing prevention and/or treat the drug or pharmaceutical composition of thrombotic disease.Wherein, thromboembolia type disease
The concept of disease is known to those skilled in the art.
In addition, the compound or pharmaceutically acceptable salt thereof of logical formula (I) structure of the invention can also be used to prevent to solidify in vitro, such as
For preventing the solidification of the biological sample containing Xa factor.
The compound or pharmaceutically acceptable salt thereof of logical formula (I) structure of the invention, can with it is one or more pharmaceutically acceptable
Carrier, excipient or diluent pharmaceutical composition is made jointly.Solid orally ingestible, liquid can be made in the pharmaceutical composition
The dosage forms such as oral preparation or injection.
The solid orally ingestible includes: tablet, dispersible tablet, enteric coatel tablets, chewable tablets, oral disintegrating tablet, capsule, granule.It adopts
Use lactose or starch as the diluent of the solid orally ingestible；Using gelatin, methylcellulose, hydroxypropyl methylcellulose, gather
Vinylpyrrolidone, starch slurry etc. are used as adhesive；Use starch, sodium carboxymethylcellulose, carboxyrnethyl starch sodium, low-substituted hydroxypropyl
Methylcellulose, crospovidone, microcrystalline cellulose are as disintegrating agent；Use talcum powder, micro- part of silica gel, tristerin, hard
Resin acid calcium or magnesium etc. are used as antiadhesives and lubricant.
The preparation method of the solid orally ingestible is the following steps are included: by active constituent and carrier and disintegration additive
Then composition mixture makes the aqueous solution of the mixture and adhesive, alcohol or aqueous alcohol solution are in suitable equipment
Wet process or dry granulation are carried out, dry particle is then added other disintegrating agents, lubricant and antiplastering aid and system appropriate is made
Agent.
The liquid oral medicine includes syrup and oral solution.
Series compound of the invention can also be administered by non-bowel form.Optimizing injection administration, including injection
Water needle, injection powder needle and primary infusion.
Series compound of the invention is effective in comparatively wide measures range, such as the dosage taken daily is 1
Within the scope of~1000mg/ people, it can divide primary or be administered for several times.The dosage for actually taking the compounds of this invention should be by doctor's root
It is determined according to related situation, these situations include the physical condition of patient, the administration route of patient, the age, weight, right
Individual reaction and the severity of symptom of drug etc..
Specific embodiment
The present invention will be further explained with reference to the examples below, and the examples are merely illustrative, is in no way intended to it
It limits the scope of the invention in any way.
Embodiment 1:
Compound I-1:N- (4- chlorphenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiophene
Azoles -4- formamide；
5.00g paraiodoaniline (compound VIII -1) is added in reaction flask, 25ml tetrahydrofuran, 4.60g triethylamine, 0.1g's
DMAP (4-dimethylaminopyridine), agitation and dropping 3.86g chloracetyl chloride, adds 25-35 insulated and stirred 2 hours, heats up 50 DEG C, protects
Solvent to the greatest extent is steamed in temperature reaction 2h, decompression, and 30ml water is added, and agitation and filtration is dry, obtains 5.6g gray solid, is compound VII -1.
5.0g compound VII -1,1.7g sodium sulfocyanate, 0.5g tetrabutylammonium iodide are put into 50ml acetonitrile, stirred
It is warming up to reflux, insulated and stirred, contact plate controls fully reacting, and solvent to the greatest extent is steamed in decompression, and 250ml water agitation and filtration is added, and filter cake is used
It washes (20ml × 2), it is dry, 3.60g gray solid is obtained, is compound VI -1.
Addition 3.2g compound VI -1 in reaction flask, 2.4g compound V, 1g cuprous iodide, 0.5g8- oxyquinoline,
1.4g potassium carbonate, 25mlDMF (dimethylformamide), nitrogen protection, stirring are warming up to reflux, and insulated and stirred, contact plate control is instead
It should be complete.Solvent to the greatest extent is steamed in decompression, and 30ml water is added, and ethyl acetate extracts (100ml × 3), merges organic phase, saturated sodium chloride water
Solution is washed (15ml × 1), and anhydrous sodium sulfate is dry, and silica gel column chromatography obtains 2.6g pale solid, is compounds Ⅳ -1.
2.5g compounds Ⅳ -1,20ml dehydrated alcohol, the lithium hydroxide that 20ml mass concentration is 15% are added in reaction flask
Aqueous solution is stirred at room temperature, and contact plate controls fully reacting.Ethyl alcohol to the greatest extent, 0-10 DEG C of 20% (mass concentration) acetic acid water of dropwise addition are steamed in decompression
Solution adjusts pH to 6-7, solid occurs, filters, and washes (25ml × 3), dry, obtains 1.6g pale solid, is compound III-
1。
In reaction flask be added 0.5g compound III -1,0.3g compound ii -1,0.5gTBTU (O- benzotriazole-N, N,
N', N'- tetramethylurea tetrafluoro boric acid), 0.5g triethylamine, 10mlDMF, nitrogen protection is stirred at room temperature, and contact plate control has been reacted
Entirely.100ml water is added in reaction solution, and ethyl acetate extracts (100ml × 3), merges organic phase, and saturated sodium-chloride water solution is washed
(15ml × 1), anhydrous sodium sulfate is dry, and silica gel column chromatography obtains 0.15g off-white powder, is chemical compounds I -1.
1H-NMR(DMSO-d6), δ (ppm): 4.012 (s, 2H), 6.507 (d, 2H), 6.679 (s, 1H), 7.023 (d,
2H),7.456(d,2H),7.738(d,2H),8.389(s,1H),10.643(s,1H),11.452(s,1H)。
Embodiment 2:
Compound I-2:N- (4- bromophenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiophene
Azoles -4- formamide；
The present embodiment uses synthetic method same as Example 1, the difference is that compound II-2 is different, specifically such as
Under,
1H-NMR(DMSO-d6), δ (ppm): 4.015 (s, 2H), 6.510 (d, 2H), 6.682 (s, 1H), 7.126 (d,
2H),7.558(d,2H),7.748(d,2H),8.688(s,1H),10.743(s,1H),11.482(s,1H)。
Embodiment 3:
Compound I-3:N- (4- bromophenyl) -2- ((the fluoro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amine
Base) thiazole -4-carboxamide；
The present embodiment uses synthetic method same as Example 1, the difference is that compound VIII-3 and II-3 are not
It is together, specific as follows,
1H-NMR(DMSO-d6), δ (ppm): 4.108 (s, 2H), 6.686 (s, 1H), 7.005 (d, 1H), 7.146 (d,
1H),7.346-7.568(m,5H),8.480(s,1H),10.446(s,1H),11.382(s,1H)。
Embodiment 4:
Compound I-4:N- (4- bromophenyl) -2- ((2- methyl -4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amine
Base) thiazole -4-carboxamide；
The present embodiment uses synthetic method same as Example 1, the difference is that compound VIII-4 and II-4 are not
It is together, specific as follows,
1H-NMR(DMSO-d6), δ (ppm): 2.140 (s, 3H), 4.106 (s, 2H), 6.510 (d, 1H), 6.686 (s,
1H),6.935(d,1H),7.226(d,2H),7.468-7.612(m,3H),8.228(s,1H),10.246(s,1H),11.382
(s,1H)。
Embodiment 5:
Compound I-5:N- (4- chlorphenyl) 2- ((the chloro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido)
Thiazole -4-carboxamide；
The present embodiment uses synthetic method same as Example 1, the difference is that compound VIII-5 is different, specifically
It is as follows,
1H-NMR(DMSO-d6), δ (ppm): 4.108 (s, 2H), 6.686 (s, 1H), 7.005 (d, 1H), 7.146 (d,
1H),7.426(d,2H),7.568-7.768(m,3H),8.690(s,1H),10.543(s,1H),11.682(s,1H)。
Embodiment 6
The compound or pharmaceutically acceptable salt thereof of logical formula (I) structure of the invention to the inhibiting effect of factor Xa in the following manner
Measurement:
Untested compound is dissolved in DMSO by various concentration, and (public purchased from HYPHEN BioMed with the Xa factor of the mankind
Department) and Tris buffer 37 DEG C warm bath 2 minutes.Then chromogenic substrate (being purchased from HYPHEN BioMed company), 37 DEG C of temperature are added
It is excited and is measured in 405nm with microplate reader after bath 50 minutes.It is compared with pure DMSO (dimethyl sulfoxide).Test substances will be contained
Test mixture excitation and the control mixture without test substances comparison, and IC is calculated by these data50Value,
It the results are shown in Table 1.
1 compound of table inhibits the active IC of FXa50
| Embodiment | 1 | 2 | 3 | 4 |
| Compound | I-1 | I-2 | I-3 | I-4 |
| IC50/nM | 30 | 25 | 42 | 48 |
In order to more fully explain implementation of the invention, following example of formulations are provided.These embodiments be only explain,
It is not intended to limit the scope of the invention.Preparation can be using any one compound in the present invention as active constituent.
Embodiment 7
The preparation of tablet:
| Prescription | 1000 dosages |
| Compound I-1 made from embodiment 1 | 80g |
| Microcrystalline cellulose | 30g |
| Pregelatinized starch | 40g |
| Lactose | 120g |
| Hydroxypropyl methylcellulose | 8g |
| Sodium carboxymethyl starch | 12g |
| Magnesium stearate | qs |
| Silica | qs |
Technique: active constituent auxiliary material is sieved with 100 mesh sieve respectively, and (half carboxymethyl forms sediment the main ingredient and auxiliary material for weighing recipe quantity
Powder sodium) it is sufficiently mixed, hydroxypropyl methylcellulose aqueous solution softwood processed in right amount is added, crosses 24 meshes, wet granular is made and is dried in 50-60 DEG C
About 2-3 hours dry in case, by remaining sodium carboxymethyl starch, magnesium stearate and silica are uniformly mixed with particle, whole grain, are surveyed
Intermediates content is determined, with special-shaped stamping.
Embodiment 8
The preparation of capsule:
| Prescription | 1000 capsule dosages |
| Compound I-3 made from embodiment 3 | 100g |
| Microcrystalline cellulose | 20g |
| Lactose | 120g |
| Low-substituted hydroxypropyl cellulose | 6g |
| 10% starch slurry | qs |
| Magnesium stearate | qs |
Technique: active constituent auxiliary material is sieved with 100 mesh sieve respectively, and the main ingredient and auxiliary material for weighing recipe quantity are sufficiently mixed, and is added
Povidone aqueous solution in right amount dry about 2-3 hours in 50-60 DEG C of baking oven by softwood processed, excessively 20 meshes, obtained wet granular, will be stearic
Sour magnesium is uniformly mixed with particle, whole grain, measures intermediates content, filling with No. 2 capsules.
Claims (10)
1. a kind of compound has the structure as shown in formula (I):
Or its pharmaceutically acceptable salt, in which:
R1Selected from fluorine, chlorine, bromine；
R2Selected from hydrogen, fluorine, chlorine, methyl.
2. compound as described in claim 1 is selected from following compounds:
N- (4- chlorphenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4-carboxamide；
N- (4- bromophenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4-carboxamide；
N- (4- bromophenyl) -2- ((the fluoro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4- formyl
Amine；
N- (4- fluorophenyl) -2- ((2- methyl -4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4- formyl
Amine；
N- (4- chlorphenyl) 2- ((the chloro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4-carboxamide；
Or its pharmaceutically acceptable salt.
3. the compound as described in any one of claims 1 or 2, wherein the pharmaceutically acceptable salt includes logical formula (I)
The salt that the compound and inorganic acid or organic acid of structure generate.
4. the preparation method of compound described in any one of claims 1 or 2, comprising the following steps:
Wherein: R1Selected from fluorine, chlorine, bromine；R2Selected from hydrogen, fluorine, chlorine, methyl；
The compound of general formula (VIII) reacts the compound for preparing general formula (VII) with chloracetyl chloride in a solvent；The chemical combination of general formula (VII)
Object prepares the compound of general formula (VI) with potassium rhodanide or sodium sulfocyanate reaction in a solvent；The compound and general formula of general formula (VI)
(V) compound reacts the compound for generating general formula (IV) in a solvent；The compound of general formula (IV) prepares general formula through hydrolysis
(III) compound；The compound of general formula (III) reacts the chemical combination for generating general formula (I) with the compound of general formula (II) in a solvent
Object.
5. compound described in any one of claims 1 or 2 is being used to prepare prevention and/or treatment thrombotic disease medicine
The purposes of object or pharmaceutical composition.
6. a kind of pharmaceutical composition, wherein contain at least one described in any item compounds of claims 1 or 2 as effectively at
Point, and contain one or more pharmaceutical acceptable carrier, diluent or excipient.
7. pharmaceutical composition as claimed in claim 6, wherein the pharmaceutical composition is solid orally ingestible, liquid port
Formulation or injection.
8. pharmaceutical composition as claimed in claim 7, wherein the solid orally ingestible is dispersible tablet, enteric coatel tablets, chewing
Piece, oral disintegrating tablet, capsule or granule.
9. pharmaceutical composition as claimed in claim 7, wherein the liquid oral medicine is syrup or oral solution.
10. pharmaceutical composition as claimed in claim 7, wherein the injection is injection water needle, injection powder needle or small
Infusion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610672153X | 2016-08-15 | ||
| CN201610672153 | 2016-08-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106518859A CN106518859A (en) | 2017-03-22 |
| CN106518859B true CN106518859B (en) | 2019-01-18 |
Family
ID=58293137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610928140.4A Active CN106518859B (en) | 2016-08-15 | 2016-10-31 | Thiazole derivative and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106518859B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101967145A (en) * | 2010-09-09 | 2011-02-09 | 华东理工大学 | Method for preparing antithrombotic medicament apixaban |
| CN102702186A (en) * | 2012-06-20 | 2012-10-03 | 安润医药科技（苏州）有限公司 | Synthesis method of rivaroxaban |
| CN103342704A (en) * | 2013-07-25 | 2013-10-09 | 甘肃皓天化学科技有限公司 | Preparation method of Apixaban as anti-thrombotic drug |
| CN103562183A (en) * | 2011-03-29 | 2014-02-05 | 赛诺菲 | Benzoic acid salt of otamixaban |
-
2016
- 2016-10-31 CN CN201610928140.4A patent/CN106518859B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101967145A (en) * | 2010-09-09 | 2011-02-09 | 华东理工大学 | Method for preparing antithrombotic medicament apixaban |
| CN103562183A (en) * | 2011-03-29 | 2014-02-05 | 赛诺菲 | Benzoic acid salt of otamixaban |
| CN102702186A (en) * | 2012-06-20 | 2012-10-03 | 安润医药科技（苏州）有限公司 | Synthesis method of rivaroxaban |
| CN103342704A (en) * | 2013-07-25 | 2013-10-09 | 甘肃皓天化学科技有限公司 | Preparation method of Apixaban as anti-thrombotic drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106518859A (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102464658B (en) | Oxazolidinone derivative and preparation method and application thereof | |
| CN101260112B (en) | Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof | |
| JP2019135258A (en) | CRYSTALLINE FORMS OF FACTOR Xa INHIBITOR | |
| KR20080003599A (en) | Gentisate of pyrrolopyrimidinone derivative and process for preparing it | |
| CN102442965B (en) | PAR-1 (protease-activated receptor-1) antagonists for treating thrombotic diseases, as well as preparation and application thereof | |
| CN104470893A (en) | Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives | |
| CN103524559A (en) | Ester derivatives of multi-substituted 4-methylamino-benzamidine as well as preparation method and application of ester derivatives | |
| CN106518859B (en) | Thiazole derivative and its preparation method and application | |
| WO2015192672A1 (en) | Benzofuran derivative, preparation method therefor, and application thereof | |
| CN106565698B (en) | Substituted thiazole analog derivative and its preparation method and application | |
| CN107445979B (en) | 6- methYl-thiazol and triazole -5- carboxamides derivatives and application | |
| CA2990747C (en) | Phenyl amino pyrimidine compound or polymorph of salt thereof | |
| RU2597423C2 (en) | Benzoate salt of otamixaban | |
| CN105130960B (en) | 1,3,5- triazine derivatives and its application | |
| KR100936278B1 (en) | Composition for prevention or treatment of cancer containing pyrimidine derivatives or phamaceutically acceptable salts thereof inhibiting protein phosphatase as an active ingredient | |
| CN102796040B (en) | 1,4-disubstituted piperazine derivatives and their preparation method and use | |
| KR20140000717A (en) | Novel anti-platelet compound addition salt | |
| CN102532107B (en) | 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof | |
| CN101602750B (en) | Naphthyl, (replacement) aryl, piperazinyl amidine compounds | |
| CN102796093B (en) | Thiomorpholine-containing pyrrole derivatives and their preparation method and use | |
| CN104710355B (en) | The preparation method and purposes of diphenyl thiourea compounds and its salt of one class containing niacinamide building block | |
| CN109879839B (en) | 6-piperazinemethyl-7-hydroxy benzofuran compound and medical application thereof | |
| CN103664930B (en) | One class is containing compound, the Preparation Method And The Use of thiazole structure | |
| CN116535361A (en) | Substituted hydroxypyrimidine xanthine oxidase inhibitor and preparation method and pharmaceutical application thereof | |
| JPS59231057A (en) | Carboxylic acid amide compound and its derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |